Longitudinal trajectories of menopausal symptoms in women receiving endocrine therapy for breast cancer compared with natural menopause.

Authors

Se Kyung Lee, Hye Rin Choi, Danbee Kang, Yoonyoung Jang, Seungho Ryu, Jeong Eon Lee, Seok Jin Nam, Seok Won Kim, Byung Joo Chae, Jai Min Ryu, Yoosoo Chang, Jonghan Yu

Published in

Breast (Edinburgh, Scotland). Volume 90. Pages 104947. Oct 21, 2026. Epub Oct 21, 2026.

Abstract

Endocrine therapy (ETx) for hormone receptor-positive breast cancer frequently induces menopausal symptoms that may compromise treatment adherence. However, longitudinal symptom trajectories compared with natural menopause remain unclear.
This longitudinal study included 5734 women from two prospective cohorts: 2583 women with breast cancer from the Breast Cancer Information Grand Round for Survivorship cohort and 3151 women without breast cancer from the Kangbuk Samsung Health Study. Menopausal symptoms were assessed using the Menopause Rating Scale (MRS). Linear mixed-effects models evaluated longitudinal changes by breast cancer status, menopausal status, and ETx use. Difference-in-differences (DiD) analyses designated premenopausal women without breast cancer as the reference group.
Among premenopausal women, ETx was associated with greater increases in total MRS scores than in women without breast cancer (DiD, 3.30; 95% CI, 2.04-4.58 at 1 year). Within the breast cancer cohort, premenopausal women receiving ETx experienced sustained increases in menopausal symptoms over 3 years, with the largest increases observed among those receiving regimens including gonadotropin-releasing hormone agonists. Among postmenopausal women, ETx was associated with modest changes in total MRS scores but a significant increase in urogenital symptoms (DiD 0.71; 95% CI, 0.26-1.16).
Compared with women without breast cancer, women receiving ETx experienced greater increases in menopausal symptoms during the first year of follow-up. Within the breast cancer cohort, elevated symptom burden persisted over 3 years, particularly among premenopausal women receiving ovarian function suppression. These findings highlight the importance of proactive symptom monitoring and supportive care during long-term endocrine therapy.

PMID:
42962501
Bibliographic data and abstract were imported from PubMed on 31 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.